Q4 Earnings Estimate for ESPR Issued By HC Wainwright

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Equities researchers at HC Wainwright issued their Q4 2026 EPS estimates for Esperion Therapeutics in a research note issued on Tuesday, March 10th. HC Wainwright analyst J. Pantginis anticipates that the biopharmaceutical company will earn $0.05 per share for the quarter. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.29) per share.

Several other equities analysts have also issued reports on ESPR. Piper Sandler started coverage on Esperion Therapeutics in a report on Tuesday, November 25th. They issued an “overweight” rating and a $9.00 target price for the company. Wall Street Zen lowered Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Cantor Fitzgerald reissued an “overweight” rating on shares of Esperion Therapeutics in a research report on Wednesday, November 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Esperion Therapeutics in a research report on Thursday, January 22nd. Finally, Needham & Company LLC lifted their target price on Esperion Therapeutics from $4.00 to $5.00 and gave the stock a “buy” rating in a research note on Tuesday, March 3rd. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $8.25.

Esperion Therapeutics Stock Performance

NASDAQ:ESPR opened at $2.59 on Wednesday. Esperion Therapeutics has a 52 week low of $0.69 and a 52 week high of $4.18. The firm has a 50-day moving average price of $3.33 and a two-hundred day moving average price of $3.14. The firm has a market cap of $619.17 million, a price-to-earnings ratio of -15.24, a price-to-earnings-growth ratio of 0.55 and a beta of 1.11.

Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings results on Tuesday, March 10th. The biopharmaceutical company reported $0.22 earnings per share for the quarter, missing the consensus estimate of $0.23 by ($0.01). The company had revenue of $168.45 million for the quarter, compared to analyst estimates of $165.12 million.

Hedge Funds Weigh In On Esperion Therapeutics

Several large investors have recently modified their holdings of the business. R Squared Ltd raised its position in shares of Esperion Therapeutics by 23.5% in the fourth quarter. R Squared Ltd now owns 15,173 shares of the biopharmaceutical company’s stock valued at $56,000 after purchasing an additional 2,890 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in Esperion Therapeutics by 10.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 38,955 shares of the biopharmaceutical company’s stock valued at $144,000 after acquiring an additional 3,614 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Esperion Therapeutics by 49.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,617 shares of the biopharmaceutical company’s stock worth $43,000 after acquiring an additional 3,822 shares in the last quarter. Eaton Financial Holdings Company LLC lifted its position in shares of Esperion Therapeutics by 9.4% during the fourth quarter. Eaton Financial Holdings Company LLC now owns 46,595 shares of the biopharmaceutical company’s stock worth $172,000 after acquiring an additional 4,000 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Esperion Therapeutics by 18.5% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 28,338 shares of the biopharmaceutical company’s stock worth $105,000 after acquiring an additional 4,422 shares during the period. Hedge funds and other institutional investors own 47.39% of the company’s stock.

Insiders Place Their Bets

In related news, CFO Benjamin Halladay sold 7,337 shares of the business’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $3.67, for a total value of $26,926.79. Following the sale, the chief financial officer directly owned 467,525 shares in the company, valued at approximately $1,715,816.75. The trade was a 1.55% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last ninety days, insiders sold 15,543 shares of company stock valued at $55,709. Company insiders own 1.70% of the company’s stock.

Key Stories Impacting Esperion Therapeutics

Here are the key news stories impacting Esperion Therapeutics this week:

• Positive Sentiment: Q4 revenue significantly beat estimates — Q4 revenue of $168.45M (+144% YoY) and FY25 total revenue of $403.1M (21% Y/Y) highlight strong top-line momentum and product growth (U.S. net product revenue +38% Y/Y). GlobeNewswire Release
• Positive Sentiment: Company announced an acquisition alongside results, which earlier sparked buying interest and was cited by retail-focused coverage as a near-term catalyst. MSN: Shares Rise After Revenue Tops Forecasts and Acquisition
• Positive Sentiment: HC Wainwright reiterated bullish stance (Buy) and published an EPS forecast for the coming quarter, signaling at least one broker remains constructive on growth/catalysts. MarketBeat: HC Wainwright Note
• Neutral Sentiment: Earnings call materials and transcripts are available and include management commentary on product uptake and upcoming catalysts; these will be parsed by investors for guidance and cadence of future launches. Yahoo Finance Transcript Seeking Alpha Transcript
• Neutral Sentiment: Reported short-interest data appears to show zero shares (likely a reporting anomaly) and should not materially change the current supply/demand picture. (No reliable short-interest signal in latest filings.)
• Negative Sentiment: EPS missed consensus by $0.01 — reported EPS $0.22 vs. $0.23 est. The small EPS miss, despite the revenue beat, is being viewed negatively by traders and was a primary driver of intraday selling pressure. Zacks: Q4 Earnings Lag
• Negative Sentiment: Market reaction: shares swung intraday (earlier pops after the acquisition/revenue beat, then declines as the EPS miss and mixed messaging landed); trading volume ran above averages, indicating active repositioning by investors. MarketBeat: Trading/Volume Summary

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.